Top Page
Wellnex Life Ltd
(Sydney:WNX)
Wellnex Life Ltd (WNX) vs. iShares MSCI Australia ETF (EWA)
Wellnex Life Ltd Business Overview & Revenue Model
Wellnex Life Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.63M | 23.63M | 16.93M | 27.89M | 18.61M | 1.20M |
| Gross Profit | 6.88M | 6.88M | -776.00K | 4.75M | 4.50M | -165.00K |
| EBITDA | -6.62M | -6.62M | -10.57M | -6.82M | -6.35M | -18.41M |
| Net Income | -15.60M | -15.60M | -13.74M | -13.85M | -7.45M | -24.69M |
Balance Sheet | ||||||
| Total Assets | 27.84M | 27.84M | 30.92M | 15.04M | 19.61M | 10.42M |
| Cash, Cash Equivalents and Short-Term Investments | 497.00K | 497.00K | 903.00K | 322.00K | 3.18M | 7.78M |
| Total Debt | 5.45M | 5.45M | 10.67M | 6.95M | 7.86M | 9.31M |
| Total Liabilities | 16.59M | 16.59M | 24.86M | 14.45M | 15.25M | 10.67M |
| Stockholders Equity | 11.25M | 11.25M | 6.06M | 594.00K | 4.36M | -249.00K |
Cash Flow | ||||||
| Free Cash Flow | -666.00K | -666.00K | -6.82M | -6.19M | -8.65M | -5.17M |
| Operating Cash Flow | -666.00K | -666.00K | -6.82M | -6.19M | -8.61M | -4.38M |
| Investing Cash Flow | -8.29M | -8.29M | -13.42M | -2.20M | -3.65M | 9.45M |
| Financing Cash Flow | 8.55M | 8.55M | 20.82M | 5.53M | 7.66M | 1.55M |
Wellnex Life Ltd Technical Analysis
Wellnex Life Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
43 Neutral | AU$31.27M | 36.96 | ― | ― | 6.76% | ― | |
43 Neutral | AU$7.33M | -0.67 | ― | ― | -21.84% | 79.99% | |
42 Neutral | AU$8.39M | -0.24 | -184.71% | ― | 39.53% | 49.99% | |
41 Neutral | AU$5.98M | -1.84 | -60.84% | ― | -18.70% | 20.83% | |
40 Underperform | AU$21.17M | -5.17 | -29.43% | ― | 102.21% | 69.47% |
Wellnex Life Ltd Corporate Events
Wellnex Life reported a sharp improvement in operating cash flow in the December 2025 quarter, with net operating cash outflow reduced to $0.16 million from $2.98 million in the prior quarter, supported by a 31.5% quarter-on-quarter rise in total revenue to $7.1 million and stronger customer cash receipts of $5.1 million. The result was driven by a 1000% surge in IP licensing revenue to $3.3 million and ongoing strength in the Pain Away brand, partially offset by a 25.5% decline in branded product sales following a deliberate move to consolidate and deprioritise non-core assets; the company ended the quarter with $0.98 million in cash and $2.01 million in undrawn facilities and reaffirmed its focus on turnaround efforts, better cash conversion, margin enhancement and cost reduction.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life has reported a significant operational turnaround for the first half of FY26, with EBITDA improving by $2.4 million year-on-year and group gross margin rising from 22.8% to 31.3%, enabling the business to reach breakeven by the end of the second quarter. The Pain Away brand continued to gain traction, delivering $3.3 million in quarterly sales, expanding margins by 7.6%, and outpacing category growth in heat patches and roll-ons, supported by new product launches and expanded distribution through Priceline, major pharmacy wholesalers, and upcoming Costco trials, positioning the company for more stable and sustainable performance into the second half of the year.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life has disclosed that an Appendix 3Y notice was lodged late due to an administrative oversight during the Christmas–New Year period, while affirming that it understands its ASX disclosure obligations and has processes in place to ensure timely future filings. The company also detailed off-market internal share transfers within entities associated with Homart Group, involving a total of 1,285,409 Wellnex Life shares moved from Homart Group to JYSF Management Pty Ltd and MYLY Management Pty Ltd, and confirmed that Homart Group Pty Ltd and MYLY Management Pty Ltd now have independent boards and are no longer associated with director Jeffrey Yeh, meaning these entities will act independently regarding their Wellnex Life holdings and upcoming ASIC filings will formalise this change in association status.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced the cessation of 1.4 million listed options (ASX code WNXAN), which carried an exercise price of $2.50 and expired on 1 January 2026 without being exercised or converted. The expiry of these options reduces the company’s potential future share dilution, effectively simplifying its capital structure and removing a class of derivative securities from its issued capital, with no immediate cash inflow resulting from option exercise.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Ltd has reported positive initial results from its turnaround strategy, focusing on scaling up the Pain Away brand and enhancing contract manufacturing revenues. The company achieved an EBITDA profit of $0.1 million in November, with year-to-date improvements in sales growth and gross margins. The introduction of Pain Away into major retailers like Costco and 7Eleven has boosted sales by 16%, and the company is on track to reach breakeven by Q2 FY2026. The board remains optimistic about further margin improvements and cost reductions in the upcoming quarters.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited, a company listed on the ASX and AIM, announced the results of its 2025 Annual General Meeting, where all resolutions except one were passed. The resignation of Mr. Ruari McGirr from the Board was noted following the failure of his re-election resolution, and the company plans to search for a new non-executive director with European market experience.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited is undergoing a strategic transformation under the leadership of Executive Chairman Ash Vesali, focusing on the global expansion of its ‘Pain Away’ brand and enhancing contract manufacturing services. The company is implementing cost-reduction measures, including streamlining operations and reassessing trade spends, aiming to reduce annual operating costs by up to 40% and achieve cashflow positive performance. These initiatives are intended to strengthen Wellnex’s market position and deliver value to shareholders.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has reached an agreement with former director George Karafotias to repay his loan by April 2026, leading to the withdrawal of a related AGM resolution. Additionally, Vivienne Zhang has resigned from the Board to focus on her role as Chief Financial Officer, with the company deciding not to immediately replace her Board position, reflecting typical ASX governance practices.
The most recent analyst rating on (AU:WNX) stock is a Sell with a A$0.16 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited has announced an agreement on a repayment schedule for a loan provided by Zack Bozinovski and his wife. The majority of the loan is set to be repaid by April 2026, aligning with the conclusion of Bozinovski’s employment with the company. This development may impact the company’s financial planning and stakeholder relations as it manages its obligations and resources.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.
Wellnex Life Limited announced that they are working towards finalizing a repayment schedule for a loan provided by Zack Bozinovski and his wife, with an expected conclusion by 7 November 2025. This update indicates ongoing negotiations and potential financial implications for Wellnex, as the company seeks to resolve outstanding financial commitments, which could impact its financial stability and stakeholder confidence.
The most recent analyst rating on (AU:WNX) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Wellnex Life Ltd stock, see the AU:WNX Stock Forecast page.